Aug 22 (Reuters) - Bristol-Myers Squibb ( BMY )-backed Zenas

BioPharma has filed to go public in the United States, a

regulatory filing showed on Thursday, underscoring improving

investor appetite for new listings.

The U.S. initial public offering market is in the early

innings of a recovery on hopes of potential interest-rate cuts

and lower market volatility.

Zenas BioPharma, an immunology and inflammation focused

biopharma company, said it has raised $358.3 million from

investors since its inception.

The company's investors include Tellus BioVentures,

Fairmount, Norwest Venture Partners, Enavate Sciences and

Bristol-Myers Squibb ( BMY ).

The firm's losses widened to $65.8 million for the six

months ended June 30, compared with $48.1 million, a year

earlier. It did not reveal the number of shares it planned to

sell and the proposed price range.

The company expects its shares to trade on the Nasdaq Global

Market under the ticker symbol 'ZBIO'. Morgan Stanley,

Jefferies, Citigroup and Guggenheim Securities are the

underwriters.

(Reporting by Manya Saini in Bengaluru; Editing by Arun Koyyur)